Rapid Scale-up of an Antiretroviral Therapy Program Before and During the COVID-19 Pandemic — Nine States, Nigeria, March 31, 2019–September 30, 2020
Emilio Dirlikov, O Adebayo, Adeola Ayo, Mahesh Swaminathan(Icahn School of Medicine at Mount Sinai), Timothy Efuntoye, Obinna Ogbanufe, Andrew T. Boyd, Chibuzor Onyenuobi, Dennis Onotu, Lisa A. Murie, Ayodele Fagbemi, Omodele Johnson Fagbamigbe, Deborah A. Conner, Ifunanya Mgbakor, Helen Chun, Viva Combs Thorsen, William Abrams, Chidozie Meribe, Mark Giambrone, Matthias Alagi, Ray W. Shiraishi, Solomon Odafe(AIDS Prevention Initiative in Nigeria), Pamela Bachanas, Ian E. Fellows, Anuli Nwaohiri, Jerry Gwamna, Akudo Ikpeazu, Nguhemen Tingir, Joy Amafah, Sarita Shah, Kathleen FitzGibbon, Michelle Williams-Sherlock, Laura Tison, Gambo Aliyu(National Agency for the Control of AIDS), Ibrahim Jahun, Ademola Oladipo, Orji Bassey, Uzoma Ene, McPaul Okoye, Obinna Nnadozie, Andrew Abutu, Ugonna C. Ijeoma, Minesh Shah, David A. Miller, Deborah Carpenter, Tedd V. Ellerbrock, Ibrahim Dalhatu, Moyosola Bamıdele
Cited by 22
Related Papers
The Lancet Nigeria Commission: investing in health and the future of the nation
|The Lancet|2022|346
Environmental Risk Factors for Infection with Mycobacterium avium Complex
|American Journal of Epidemiology|2006|105
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study
|AIDS Research and Therapy|2010|83
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
|The Lancet HIV|2019|61
Patients’ demographic and clinical characteristics and level of care associated with lost to follow‐up and mortality in adult patients on first‐line ART in Nigerian hospitals
|Journal of the International AIDS Society|2012|52